comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 22:58:09 - browse：77315

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Novo Nordisk to buy Cardior, building up pipeline of heart drugs

hotspot

WSS

Stories you might have missed in 2023: health, science, medicine

Life science postdocs should get big pay hike, NIH panel says

Texas board proposes rules on abortion law emergency exemption

American taxpayers paid $1.8 trillion in health care costs in 2022

FDA early review: GLP

Life science postdocs should get big pay hike, NIH panel says

hotspot

comprehensive

hotspot

Supreme Court strikes down use of affirmative action

Allen Institute goes after foundational questions, CEO Costa says

Continuity nursing helped my family in our darkest PICU moments

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Illumina, CRISPR, Regeneron

DIEP, the 'gold standard' of breast reconstruction, is under threat

At JPM 2024, hospital systems pitch financial strength to investors

In age of alternative facts, a scholarly course on calling out crap

Yancopoulos of Regeneron works to expand Dupixent success

knowledge

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

STAT Virtual Event: JPM Recap, Live!

Pregnancy ages women, but effects reverse after delivery

With Wegovy coverage, Medicare patients may face high costs

Physician assistants need a new name. Here's what it should be

Fauci's latest grilling in Congress: 9 hours, behind closed doors

entertainment

Wikipedia

hotspot

focus